Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
This partnership will explore in more detail the function and interaction of genes and proteins in cancer, and apply new genome-altering technologies, such as CRISPR, to create sophisticated models of the disease for research.
The centre will be a dedicated world-class resource for AstraZeneca and Cancer Research UK’s academics and alliance partners working at all stages of translational research, from target discovery and validation, to assessing novel drug combinations.
